About: Ultra-sensitive and high-throughput CRISPR-Powered COVID-19 diagnosis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Ultra-sensitive and high-throughput CRISPR-Powered COVID-19 diagnosis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Ultra-sensitive and high-throughput CRISPR-Powered COVID-19 diagnosis
Creator	Tian, Di Liu, Yang Ning, Bo Huang, Zhen Lai, C Lin, Zhen Yin, A Huang, Z Tian, D Hu, X Lin, Y Drouin, Arnaud Fusco, Dahlene Hu, Tony Lai, Weihua Lyon, Christopher Yin, Xiaoming Fusco, Fusco, W Lyon, Z
Source	Elsevier; Medline; PMC; WHO
abstract	Recent research suggests that SARS-CoV-2-infected individuals can be highly infectious while asymptomatic or pre-symptomatic, and that an infected person may infect 5.6 other individuals on average. This situation highlights the need for rapid, sensitive SARS-CoV-2 diagnostic assays capable of high-throughput operation that can preferably utilize existing equipment to facilitate broad, large-scale screening efforts. We have developed a CRISPR-based assay that can meet all these criteria. This assay utilizes a custom CRISPR Cas12a/gRNA complex and a fluorescent probe to amplify target amplicons produced by standard RT-PCR or isothermal recombinase polymerase amplification (RPA), to allow sensitive detection at sites not equipped with real-time PCR systems required for qPCR diagnostics. We found this approach allowed sensitive and robust detection of SARS-CoV-2 positive samples, with a sample-to-answer time of ∼50 min, and a limit of detection of 2 copies per sample. CRISPR assay diagnostic results obtained nasal swab samples of individuals with suspected COVID-19 cases were comparable to paired results from a CDC-approved qPCR assay performed in a state testing lab, and superior to those produced by same assay in a clinical lab, where the qPCR assay exhibited multiple invalid or inconclusive results. Our assay also demonstrated greater analytical sensitivity and more robust diagnostic performance than other recently reported CRISPR-based assays. Based on these findings, we believe that a CRISPR-based fluorescent application has potential to improve current COVID-19 screening efforts.
has issue date	2020-05-23(xsd:dateTime)
bibo:doi	10.1016/j.bios.2020.112316
bibo:pmid	32553350
has license	no-cc
sha1sum (hex)	c8e9fe46a5fe98d7cd224f08cfe79dc5ec518380
schema:url	https://doi.org/10.1016/j.bios.2020.112316
resource representing a document's title	Ultra-sensitive and high-throughput CRISPR-Powered COVID-19 diagnosis
has PubMed Central identifier	PMC7245202
has PubMed identifier	32553350
schema:publication	Biosens Bioelectron
resource representing a document's body	covid:c8e9fe46a5fe98d7cd224f08cfe79dc5ec518380#body_text
is schema:about of	named entity 'probe' named entity 'demonstrated' named entity 'Our' named entity 'testing' named entity 'paired' named entity 'sensitivity' named entity 'amplification' named entity 'performed' named entity 'qPCR' named entity 'samples' named entity 'assay' named entity 'CRISPR' named entity 'detection' named entity 'greater' named entity 'highly' named entity 'assays' named entity 'highlights' named entity 'infected' named entity 'infect' named entity 'isothermal' named entity 'COVID-19' named entity 'qPCR' named entity 'high-throughput' named entity 'fluorescent' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'CRISPR' named entity 'fluorescent' named entity 'limit of detection' named entity 'RT-PCR' named entity 'qPCR' named entity 'gRNA' named entity 'Cas12a' named entity 'CDC' named entity 'CRISPR' named entity 'qPCR' named entity 'COVID' named entity 'average' named entity 'individuals' named entity 'isothermal' named entity 'Ultra-sensitive' named entity 'APPROVED' named entity 'NASAL' named entity 'AMPLIFICATION' named entity 'SAMPLE' named entity 'PERFORMED' named entity 'SITUATION' named entity 'MEET' named entity 'CURRENT' named entity 'SYMPTOMATIC' named entity 'SUSPECTED' named entity 'SYSTEMS' named entity 'CRISPR' named entity 'EQUIPMENT' named entity 'ASSAY' named entity 'APPLICATION' named entity 'TARGET' named entity 'LIMIT OF DETECTION' named entity 'INFECT' named entity 'SCALE' named entity 'ROBUST'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software